Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy

Published:August 18, 2021DOI:



      Achieving sustained virologic response (SVR) to antiviral therapy for hepatitis C virus (HCV) infection is an important step for eliminating HCV infection worldwide. However, recurrence of HCV viremia may occur due to HCV reinfection and confirmation of the long-term absence of HCV viremia, i.e., the absence of HCV reinfection, is necessary in post-SVR patients. In this report, we studied the long-term results of serum HCV RNA measurements in patients with SVR in whom serum HCV RNA was monitored over decades.


      Serum HCV RNA was measured at every visit in a total of 1,392 SVR patients who underwent regular visits to the hospital after SVR, of whom 434 patients (31.2%) had continued regular visits for more than 10 years.


      No patients demonstrated positive serum HCV RNA during follow-up after SVR with a total of 23,187 HCV RNA tests.


      This study confirmed the absence of reinfection with HCV in Japanese general population with SVR for decades. Once HCV had been eradicated by anti-HCV therapy, HCV infection rarely recurs even in a lifetime in Japan, unless patients are in high risk group of HCV infection and drop out for follow-up.


      To read this article in full you will need to make a payment


      Subscribe to Journal of Infection and Chemotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Formann E.
        • Steindl-Munda P.
        • Hofer H.
        • Jessner W.
        • Bergholz U.
        • Gurguta C.
        • et al.
        Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
        Aliment Pharmacol Ther. 2006; 23: 507-511
        • Giannini E.G.
        • Basso M.
        • Savarino V.
        • Picciotto A.
        Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
        Aliment Pharmacol Ther. 2010; 31: 502-508
        • Hayashi K.
        • Ishigami M.
        • Ishizu Y.
        • Kuzuya T.
        • Honda T.
        • Hirooka Y.
        • et al.
        Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
        J Viral Hepat. 2018; 25: 1446-1451
        • Midgard H.
        • Bjøro B.
        • Mæland A.
        • Konopski Z.
        • Kileng H.
        • Damås J.K.
        • et al.
        Hepatitis C reinfection after sustained virological response.
        J Hepatol. 2016; 64: 1020-1026
        • Simmons B.
        • Saleem J.
        • Hill A.
        • Riley R.D.
        • Cooke G.S.
        Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis.
        Clin Infect Dis. 2016; 62: 683-694
        • Toyoda H.
        • Kumada T.
        • Takaguchi K.
        • Shimada N.
        • Tanaka J.
        Changes in hepatitis C virus genotype distribution in Japan.
        Epidemiol Infect. 2014; 142: 2624-2628
        • Chung H.
        • Ueda T.
        • Kudo M.
        Changing trends in hepatitis C infection over the past 50 years in Japan.
        Intervirology. 2010; 53: 39-43
        • Bourliere M.
        • Barberin J.M.
        • Rotily M.
        • Guagliardo V.
        • Portal I.
        • Lecomte L.
        • et al.
        Epidemiological changes in hepatitis C genotypes in France: evidence in intravenous drug users.
        J Viral Hepat. 2002; 9: 62-70
        • Chlabicz S.
        • Flisiak R.
        • Kowalczuk O.
        • Grzeszczuk A.
        • Pytel-Krolczuk B.
        • Prokopowicz D.
        • et al.
        Changing HCV genotype distribution in Poland – relation to source and time of infection.
        J Clin Virol. 2008; 42: 156-159